Figure 5
Figure 5. CML induction in OB ablation model. (A) Schematic representation of generation of OB ablation CML induction mice. (B) Schematic representation of CML induction. (C) WBC counts, percentage of neutrophils, and Gr-1+CD11b+ cells in the PB of control and OB ablated BCR/ABL mice at 6 weeks after BCR/ABL induction. (D) Survival curve for control or OB ablated BCR/ABL mice. (E-F) After 28 days of GCV treatment and 3 weeks of BCR-ABL induction, CD45.2 LTHSCs (400 cells per mouse) were sorted from control or OB ablated BCR/ABL mice and transplanted into CD45.1 recipient mice. (E) Survival curves for transplanted mice. (F) Donor cell engraftment, WBC counts, and percentage of Gr-1+CD11b+ cells in PB was monitored. *P < .05. Error bars represent mean ± SEM.

CML induction in OB ablation model. (A) Schematic representation of generation of OB ablation CML induction mice. (B) Schematic representation of CML induction. (C) WBC counts, percentage of neutrophils, and Gr-1+CD11b+ cells in the PB of control and OB ablated BCR/ABL mice at 6 weeks after BCR/ABL induction. (D) Survival curve for control or OB ablated BCR/ABL mice. (E-F) After 28 days of GCV treatment and 3 weeks of BCR-ABL induction, CD45.2 LTHSCs (400 cells per mouse) were sorted from control or OB ablated BCR/ABL mice and transplanted into CD45.1 recipient mice. (E) Survival curves for transplanted mice. (F) Donor cell engraftment, WBC counts, and percentage of Gr-1+CD11b+ cells in PB was monitored. *P < .05. Error bars represent mean ± SEM.

Close Modal

or Create an Account

Close Modal
Close Modal